Thermo Fisher Scientific Inc. Secures Leadership Position in ISG Provider Lens™ Report

Thermo Fisher Scientific Inc., a dominant force in the life sciences sector, has been recognized as a Leader among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report. This accolade reflects the company's unwavering commitment to digital innovation throughout the clinical development continuum, reinforcing its position as a pioneer in the utilization of artificial intelligence (AI) within clinical trials.

The ISG Provider Lens™ report, conducted by Information Services Group (ISG), specifically highlights the exceptional capabilities of Thermo Fisher’s PPD™ clinical research business. The report evaluates various providers based on their technology innovation, portfolio strength, and competitive positioning. Thermo Fisher’s end-to-end approach to clinical development garnered positive attention, particularly its integration of decentralized and hybrid trial models with sophisticated data analytics.

Thermo Fisher’s strategic incorporation of digital technologies and AI-driven insights throughout the clinical trial lifecycle is instrumental in aiding clients to minimize operational complexities and enhance the predictability of their global development programs. This comprehensive strategy positions Thermo Fisher at the forefront of clinical research innovation.

In terms of patient engagement, the report notes Thermo Fisher’s effective data-driven strategies aimed at improving recruitment and retention rates. The company has developed digital platforms that broaden access to clinical trials, thereby accelerating enrollment timelines. Such initiatives ensure that study designs are inclusive of all clinically relevant populations, a critical factor in advancing medical research and ensuring diverse data collection.

The report also commends Thermo Fisher for its advancements in pharmacovigilance and regulatory affairs. The company is at the vanguard of employing AI and machine learning to enhance safety case processing, signal detection, and regulatory intelligence. These innovations facilitate proactive risk management and bolster compliance across global markets, ensuring that therapies meet the highest safety standards.

Krishna Cheriath, Vice President and Head of Clinical Research Digital and AI at Thermo Fisher Scientific, expressed pride in the recognition, stating, “This recognition affirms our leadership as a global CRO advancing digital clinical trials through AI and data-driven innovation across every stage of development.” He emphasized the company’s dedication to creating a more connected, patient-centric, and AI-enabled future for clinical research, ultimately aimed at expediting the delivery of safe and effective therapies to patients worldwide.

Sneha Jayanth, ISG Lead Analyst, further elaborated on Thermo Fisher’s capabilities, stating, “The PPD clinical research business exemplifies the next-generation CRO model, where operational scale is enhanced by data, AI and patient-centric design to deliver predictable, high-quality clinical outcomes at global scale.”

The recognition from the ISG Provider Lens™ solidifies Thermo Fisher Scientific’s status as a leader in the life sciences sector, particularly in the realm of clinical research. With over $45 billion in annual revenue and a mission to enhance global health, safety, and cleanliness, Thermo Fisher continues to push the boundaries of innovation. The company remains committed to supporting its clients with cutting-edge technologies and services, ensuring that medical advancements can reach patients in need more efficiently and effectively than ever before.